Related Experiment Video
Updated: Aug 21, 2026
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance
1Division of Gastroenterology, University of Washington, School of Medicine, Seattle, Washington 98195, USA.
Insights
Aspirin helps prevent cardiovascular events but increases gastrointestinal risks. Co-therapy with proton pump inhibitors (PPIs) effectively reduces these gastrointestinal injuries, with PPIs generally better tolerated than misoprostol.
Area of Science:
- Cardiology
- Gastroenterology
- Pharmacology
Background:
- Aspirin is crucial for preventing cardiovascular thrombotic events in patients with or at risk for cardiovascular disease (CVD).
- Aspirin use is associated with an increased risk of gastrointestinal (GI) injury, including ulceration and hemorrhage, due to its antiplatelet and gastric mucosal effects.
- While aspirin reduces the risk of a first myocardial infarction (MI) in those with established CVD, its effects on stroke and vascular death are less conclusive.
Purpose of the Study:
- To evaluate the efficacy and safety of aspirin in cardiovascular disease (CVD) prevention.
- To assess the gastrointestinal (GI) risks associated with aspirin therapy.
- To determine the effectiveness of gastroprotective agents in mitigating aspirin-induced GI complications.
Main Methods:
- Review of studies on aspirin's role in cardiovascular event prevention.
- Analysis of data on aspirin-associated gastrointestinal (GI) injury and complications.
- Comparison of gastroprotective agents, including proton pump inhibitors (PPIs) and misoprostol, in reducing GI risks.
Main Results:
- Aspirin use is recommended for secondary prevention in patients with established CVD, balancing cardiovascular benefits against GI risks.
- Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with aspirin may increase the risk for GI events.
- Co-therapy with proton pump inhibitors (PPIs) or misoprostol significantly decreases the risk for GI injury and complications, with PPIs demonstrating better tolerability.
Conclusions:
- Aspirin remains a key medication for cardiovascular event prevention, particularly in secondary prevention settings.
- Patients on aspirin therapy require assessment for GI injury risk factors.
- Proton pump inhibitors (PPIs) are recommended as a well-tolerated and effective strategy to reduce aspirin-induced gastrointestinal complications.
Abstract:
Aspirin is a very useful medication for the prevention of cardiovascular thrombotic events in patients with or those at risk for cardiovascular disease (CVD). Aspirin, however, carries an increased risk for gastrointestinal (GI) injury (e.g., ulceration) and its complications (e.g., hemorrhage), which may be caused by its antiplatelet and gastric mucosal effects. In those with established CVD, aspirin use has been documented to decrease the risk of a first myocardial infarction (MI). Its effects on stroke and vascular death are less conclusive. The use of aspirin in these individuals is recommended only for those whose risk for cardiovascular events (based on coronary risk assessment tools) is sufficiently high that it outweighs the risk for GI complications. Secondary prevention refers to the use of aspirin to prevent cardiovascular events in patients with established CVD such as an MI, stroke, or angina. The use of aspirin in these individuals is recommended based on a documented decrease in future cardiovascular events and mortality. The risk for GI events with aspirin is at least additive to the risk for these events in those who also are receiving therapy with a nonsteroidal anti-inflammatory drug. Patients being treated with aspirin, even at 81 mg/day for cardioprotection, should be assessed for factors that increase the risk for GI injury. Studies have confirmed that co-therapy with a proton pump inhibitor (PPI) or misoprostol decreases the risk for GI injury and complications. Although both classes of such gastroprotective agents are effective, treatment with a PPI is tolerated better, with fewer patients discontinuing the drug because of side effects such as diarrhea.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Drug toxicity: Drug–Drug Interaction
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...